Aeglea BioTherapeutics, Inc. (AGLE)
(Delayed Data from NSDQ)
$7.82 USD
+0.07 (0.90%)
Updated Mar 3, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.41% |
| 2 | Buy | 17.88% |
| 3 | Hold | 9.48% |
| 4 | Sell | 5.03% |
| 5 | Strong Sell | 1.87% |
| S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
4-Sell of 5 4
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
F Value F Growth D Momentum F VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
View All Zacks #1 Ranked Stocks
Zacks News
Aeglea (AGLE) Upgraded to Buy: Here's Why
by Zacks Equity Research
Aeglea (AGLE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AGLEPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Is a Surprise Coming for Aeglea (AGLE) This Earnings Season?
by Zacks Equity Research
Aeglea (AGLE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AGLEPositive Net Change
earnings medical
Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) will provide updates on earnings, revenues and other pipeline developments when its releases third-quarter 2020 results.
BMYNegative Net Change ZTSNegative Net Change AGLEPositive Net Change AXLANegative Net Change
pharmaceuticals
Aeglea (AGLE) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Aeglea (AGLE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
AVEONegative Net Change AGLEPositive Net Change
Here's Why Momentum Investors Will Love Aeglea Biotherapeutics (AGLE)
by Zacks Equity Research
Does Aeglea Biotherapeutics (AGLE) have what it takes to be a top stock pick for momentum investors? Let's find out.
AGLEPositive Net Change
momentum-investor momentum-stocks price-change volume
Has Aeglea BioTherapeutics (AGLE) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AGLE) Outperforming Other Medical Stocks This Year?
AGLEPositive Net Change
momentum-stocks sectors stock-market-sectors
Aeglea BioTherapeutics (AGLE) Catches Eye: Stock Jumps 5.1%
by Zacks Equity Research
Aeglea BioTherapeutics (AGLE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
AGLEPositive Net Change APLTNegative Net Change
medical
Has Aeglea BioTherapeutics (AGLE) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AGLE) Outperforming Other Medical Stocks This Year?
AGLEPositive Net Change
momentum-stocks sectors stock-market-sectors
Why Aeglea BioTherapeutics (AGLE) Stock Might be a Great Pick
by Zacks Equity Research
Aeglea BioTherapeutics (AGLE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
AGLEPositive Net Change
medical
Zacks.com featured highlights include: Aeglea BioTherapeutics and Passage Bio
by Zacks Equity Research
Zacks.com featured highlights include: Aeglea BioTherapeutics and Passage Bio
AGLEPositive Net Change PASGPositive Net Change
medical
New Analyst Coverage Puts Spotlight on These 2 Stocks
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
AGLEPositive Net Change PASGPositive Net Change
finance medical
Aeglea BioTherapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aeglea BioTherapeutics
AGLEPositive Net Change
medical
Menlo Therapeutics (MNLO) Catches Eye: Stock Jumps 7.1%
by Zacks Equity Research
Menlo Therapeutics (MNLO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
AGLEPositive Net Change MNLONegative Net Change
medical
Is Aeglea BioTherapeutics (AGLE) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (AGLE) Outperforming Other Medical Stocks This Year?
AGLEPositive Net Change
momentum-stocks sectors stock-market-sectors
Zacks.com featured highlights include: Aeglea BioTherapeutics, VeriSign, Sequans Communications and New Jersey Resources
by Zacks Equity Research
Zacks.com featured highlights include: Aeglea BioTherapeutics, VeriSign, Sequans Communications and New Jersey Resources
VRSNNegative Net Change SQNSNegative Net Change NJRPositive Net Change AGLEPositive Net Change
computers medical
4 Stocks in the Limelight on New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
VRSNNegative Net Change SQNSNegative Net Change NJRPositive Net Change AGLEPositive Net Change
finance
Find Strong Stocks During the Coronavirus with New Analyst Coverage
by Benjamin Rains
Today we screened for strong stocks that recently received new analyst coverage...
VRSNNegative Net Change SQNSNegative Net Change AGLEPositive Net Change
biotechs earnings semiconductor tech-stocks
Is Aeglea BioTherapeutics (AGLE) Stock a Solid Choice Right Now?
by Zacks Equity Research
Aeglea BioTherapeutics (AGLE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
AGLEPositive Net Change
medical
Aeglea BioTherapeutics, Inc. (AGLE) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aeglea BioTherapeutics, Inc. (AGLE).
AGLEPositive Net Change
medical
Aeglea (AGLE) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Aeglea (AGLE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AGLEPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Aeglea (AGLE) Reports New Positive Data for Pegzilarginase
by Zacks Equity Research
Aeglea (AGLE) reports new positive data for pegzilarginase in patients with Arginase 1 Deficiency.
MRKPositive Net Change JNJNegative Net Change BAYRYNegative Net Change AGLEPositive Net Change
biotechs
Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval
by Zacks Equity Research
Shares of Dermira, Inc. (DERM) increase about 5% after the FDA approved its excessive underarm sweating drug, Qbrexza.
ANIPNegative Net Change AGLEPositive Net Change JAZZNegative Net Change DERMNegative Net Change
Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern.
BMRNNegative Net Change SRPTNegative Net Change ANIPNegative Net Change AGLEPositive Net Change
Alkermes' Aristada Initio Approved by FDA for Schizophrenia
by Zacks Equity Research
FDA approves Alkermes' (ALKS) Aristada Initio (aripiprazole lauroxil) for the treatment of schizophrenia in adults.
ILMNNegative Net Change ALKSNegative Net Change ANIPNegative Net Change AGLEPositive Net Change
Roche's Breast Cancer Study Meets Co-Primary Endpoint
by Zacks Equity Research
Phase III IMpassion130 study shows that Roche???s (RHHBY) Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.
RHHBYNegative Net Change ILMNNegative Net Change ANIPNegative Net Change AGLEPositive Net Change